Improved Glycemic Control Achieved by Switching to Insulin Degludec in Insulin-Treated Patients with Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study

Inzucchi SE(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

Bergenstal RM(2014)Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study J Med Econ. 17 21-31

Buse JB(2010)Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study Prim Care Diabetes. 4 85-89

Curtis B(2012)Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin Pharm Res 29 2104-2114

Lage MJ(2013)Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec Biochemistry 52 295-309

Dale J(2011)Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec Diabetologia 54 S426-950

Martin S(2012)Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes Diabetes Obes Metab 14 944-864

Gadsby R(2012)Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 14 859-1586

Jonassen I(2016)Efficacy and safety of LixiLan, a titratable fixed-ratio combination of Lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial Diabetes Care 39 1579-549

Havelund S(2007)The treat-to-target alC approach to control type 2 diabetes and prevent complications Adv Ther. 24 545-864

Inzucchi SE(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-149

Bergenstal RM(2014)Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study J Med Econ. 17 21-31

Buse JB(2010)Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study Prim Care Diabetes. 4 85-89

Curtis B(2012)Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin Pharm Res 29 2104-2114

Lage MJ(2013)Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec Biochemistry 52 295-309

Dale J(2011)Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec Diabetologia 54 S426-950

Martin S(2012)Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes Diabetes Obes Metab 14 944-864

Gadsby R(2012)Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 14 859-1586

Jonassen I(2016)Efficacy and safety of LixiLan, a titratable fixed-ratio combination of Lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial Diabetes Care 39 1579-549

Havelund S(2007)The treat-to-target alC approach to control type 2 diabetes and prevent complications Adv Ther. 24 545-864